Elevance Health(ELV)
搜索文档
Barclays Adjusts Elevance Health (ELV) PT to $393 While Maintaining Overweight Rating
Yahoo Finance· 2026-01-31 20:48
分析师评级与目标价调整 - 2025年1月30日,巴克莱将Elevance Health的目标价从404美元下调至393美元,维持“超配”评级 [1] - 2025年1月29日,Guggenheim分析师Jason Cassorla将目标价从414美元下调至396美元,维持“买入”评级,该调整基于重新校准后的2026年预期 [1] - 同日,德意志银行将目标价从320美元上调至332美元,维持“持有”评级,认为公司2026年展望可能已触底 [2] - 瑞银将目标价从425美元下调至400美元,维持“买入”评级 [3] 公司业务概况 - Elevance Health Inc 是一家在美国运营的健康福利公司,股票代码为 NYSE:ELV [1][2][3] - 公司业务分为四个板块:健康福利、CarelonRx、Carelon服务、以及企业与其他 [3]
Health Insurance Stock Could Rebound Off Historically Bullish Signal
Schaeffers Investment Research· 2026-01-30 03:44
Elevance Health Inc (NYSE:ELV) stock yesterday enjoyed its biggest single-day percentage gain since May 2024 after reporting $547 million in profits, but it wasn’t enough to erase its worst day since March 2020 in the previous session, after the Centers for Medicare & Medicaid Services proposed to raise Medicare Advantage payment rates by only 0.09% in 2027. The good news is that this bear gap placed ELV near a trendline with historically bullish implications, which could help it trim its 14.2% year-over-ye ...
Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums
ZACKS· 2026-01-29 02:25
Key Takeaways Elevance Health posted Q4 adjusted EPS of $3.33, beating consensus by 7.3% despite revenues missing estimates.ELV's premiums rose 12.3% year over year, driven by higher yields and Medicare Advantage membership growth.Carelon revenues jumped 27% on buyouts and risk-based services, while overall medical membership declined.Elevance Health, Inc. (ELV) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $3.33, which surpassed the Zacks Consensus Estimate by 7.3%. The bottom line rose ...
Elevance Health Earnings Add to Medicare Pain. Why The Stock Is Rising Anyway.
Barrons· 2026-01-29 01:35
Elevance Health Earnings Add to Medicare Pain. Why The Stock Is Rising Anyway. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Elevance Health Earnings Add to Medicare Pain. Why The Stock Is Rising Anyway.By [Mackenzie Tatananni]and [Alex K ...
Elevance Health Q4 Earnings Review: No Sign Of An End To The Pain
Seeking Alpha· 2026-01-29 00:03
The author has an honours degree in economics and politics with a focus on economic development. With 36 years of experience in executive management he has extensive knowledge of insurance/reinsurance, Global and Asia Pacific markets, climate change and ESG. He invests in his personal capacity.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and ...
Elevance forecasts 2026 profit below estimates, flags revenue decline
Yahoo Finance· 2026-01-28 23:20
By Sriparna Roy and Sneha S K Jan 28 (Reuters) - Elevance Health said on Wednesday it expects revenue to fall slightly in 2026 and forecast full-year profit below Wall Street estimates, signaling that elevated medical costs will continue to weigh on insurers. The dour outlook sent shares of the health insurer down more than 7% before the bell. “We view 2026 as a year of execution and repositioning across Medicaid, Medicare Advantage and (Obamacare plans),” said CEO Gail Boudreaux, adding the forecas ...
Elevance Health ELV Q4 2025 Earnings Transcript
Yahoo Finance· 2026-01-28 23:13
Second, even in a dynamic environment, we are acting decisively in the areas within our control to strengthen margins, reduce volatility, and improve the consistency of our performance. And third, as those actions take hold, we expect to return to at least 12% adjusted EPS growth in 2027 off our ending 2026 earnings baseline supported by the earnings power of our diversified platform. Consistent with that approach, we are establishing 2026 adjusted diluted earnings per share guidance of at least $25.50. As ...
Elevance Health Q4 Earnings Call Highlights
Yahoo Finance· 2026-01-28 23:09
2025年第四季度及全年财务业绩 - 第四季度调整后稀释每股收益为3.33美元,全年为30.29美元 [1] - 第四季度业绩受益于高于预期的税收优惠,使全年非经常性项目贡献增至每股3.75美元 [1] - 第四季度营业收入为493亿美元,同比增长10% [4][7] - 全年营业现金流为43亿美元,约为GAAP净收入的0.8倍 [9] - 2025年公司通过回购和股息向股东返还了41亿美元资本 [4][9] 2026年财务指引与增长目标 - 设定2026年调整后稀释每股收益指引为至少25.50美元 [2][6] - 预计2026年营业现金流至少为55亿美元 [4][9] - 重申计划在2027年以2026年底的收益为基准,恢复至少12%的调整后每股收益增长 [3][6][23] - 预计2026年营业收入将出现低个位数百分比下降,主要受风险会员数下降影响 [22] 会员数与业务组合调整 - 2025年底总会员数为4520万,同比减少约50万,主要因医疗补助资格重新核验导致会员减少 [8] - 预计2026年医疗补助会员将减少约75万,运营利润率约为-1.75% [5][10][12] - 预计2026年联邦医疗保险优势会员数将下降高十位数百分比范围,同时目标实现至少2%的利润率 [5][13] - 预计2026年底个人ACA市场会员数至少为90万 [5][14] - 预计2026年雇主团体风险会员数将下降高个位数百分比范围 [15] 各业务板块成本趋势与利润率展望 - 2026年综合医疗损失率预计为90.2%,上下浮动50个基点 [22] - 2026年调整后运营费用率预计为10.6%,上下浮动50个基点 [22] - 医疗补助计划成本趋势预计为中个位数百分比,但仍高于历史水平且费率滞后 [26] - 个人ACA市场成本趋势加速,因补贴到期后风险池严重程度预期上升 [26] - 联邦医疗保险报告的成本趋势预计在2026年更高,主要受会员结构变化影响 [26] Carelon业务发展与长期利润率目标 - Carelon业务需求强劲,但近期增长将受健康计划会员数减少的制约 [16] - 调整了CarelonRx的长期利润率预期,因增长构成变化及专科药房扩张 [17] - Carelon Services采取基于费用和基于风险的混合安排模式 [18] - 更新长期企业利润率目标至5%–6% [4][19] - 健康福利板块利润率目标调整反映了业务组合变化,而非各业务线基础利润率预期的改变 [19][20] 资本配置与股东回报 - 第四季度以4.7亿美元回购了140万股股票,全年回购总额达26亿美元 [9] - 2026年计划分配约23亿美元用于股票回购 [4][9] - 2025年第四季度综合福利费用率为93.5%,全年为90% [7] - 2025年第四季度调整后运营费用率为10.8%,全年为10.5% [7] - 应付索赔天数为41.3天,管理层预计2026年将保持在40天出头的低水平 [9] 2026年战略主题与运营重点 - 管理层强调“执行与重新定位”是2026年的核心主题 [3] - 公司利用坚实的底层业绩,将原计划2026年的一些投资提前,并支持年初的劳动力相关计划 [1] - 在商业业务中强调定价纪律和利润率门槛 [15] - 预计2026年调整后每股收益约三分之二将在上半年实现,其中65%在第一季度 [23] - 2027年增长路径将得到商业、医保、Carelon、医疗补助等多方面杠杆的支持 [23]
US Health Insurer Elevance Health Issues Soft Outlook, Lower Premium Forecast For 2026
Benzinga· 2026-01-28 23:06
Elevance Health Inc. (NYSE:ELV) shares fell after the health insurer reported mixed fourth-quarter 2025 earnings and bleak fiscal 2026 guidance. The stock has recovered most of its loss from the premarket sessionEarnings SnapshotThe company reported fourth-quarter 2025 revenues of $49.3 billion, up 10% year over year, below the consensus of $49.82 billion. Operating revenue was $197.6 billion in 2025, up 13%.The increase in revenue for the quarter and year was driven by higherpremium yields in the Health Be ...
Elevance Health(ELV) - 2025 Q4 - Earnings Call Transcript
2026-01-28 22:32
Elevance Health (NYSE:ELV) Q4 2025 Earnings call January 28, 2026 08:30 AM ET Company ParticipantsA.J. Rice - Managing Director and Equity ResearchAndrew Mok - Director, Equity ResearchBen Hendrix - VP and Assistant VPDave Windley - Managing DirectorFelicia Norwood - President, Government Health BenefitsGail Boudreaux - President and CEOLisa Gill - Managing DirectorMark Kaye - CFOMorgan Kendrick - President, Commercial Health BenefitsNathan Rich - VP of Investor RelationsPete Haytaian - President of Carelon ...